Clinical Trials Search
A Phase 3, Open-Label, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (Ace-536) Versus Epoetin Alfa for the Treatment Of Anemia Due To IPSS-R Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes (Mds) In Esa Naïve Subjects Who Require Red Blood Cell Transfusions The Commands Trial
This clinical research study is of an investigational drug, called luspatercept, which is being developed to treat a number of different conditions, including anemia, as a result of MDS.
Primary objective: To evaluate the efficacy of luspatercept on RBC transfusion independence (RBC-TI) compared to epoetin alfa for the treatment of anemia due to IPSS-R very low, low, or intermediate risk MDS in ESA naïve subjects who require RBC transfusions
ACE-536 (Luspatercept); Epoetin Alfa (erythropoietin); Luspatercept (); Not Applicable ()